Science 37

Case Study: Narcolepsy

Phase 3 | Rare Disease, Neurology

Challenge

The study targeting a small and geographically dispersed patient population, made traditional site-based access and optimal participation impractical. Several key obstacles complicated enrollment:

Limited Site Reach: Patients were spread across wide regions, and few lived near traditional research sites.

Strict Eligibility Criteria: Requirements such as being on a specific medication and maintaining precise blood pressure ranges significantly narrowed the pool of qualified candidates, further limiting the potential for enrollment through brick & mortar sites.

High Site Activation Burden: To achieve enrollment goals using a traditional model, the sponsor would have had to activate a large number of sites—driving up costs, timelines, and complexity.

Participant Burden: Even those who lived near sites were unwilling to travel for multiple visits in a short time frame due to the inconvenience and time commitment required.

Solution

Science 37's Direct-to-Patient Site helped the sponsor streamline enrollment and expand access by bringing the trial directly to patients—regardless of their location.

Single, Direct-to-Patient Site: Acting as the primary site of record, Science 37 successfully enrolled the majority of study participants across the U.S., eliminating the need for the sponsor to qualify and initiate numerous traditional sites.

Research-Grade Nursing: Science 37's nation-wide network of in-house mobile research-grade nurses conducted in-home visits, including repeat assessments just three days apart—dramatically reducing participant burden and travel requirements.

Streamlined Eligibility Confirmation: Medical records retrieval and review quickly enabled upfront confirmation of eligibility and minimized screening delays.

Science 37 Results

Enrolled
55%
of Total Study Participants

98%
Visit Completion Rate

Top Enrolling Site
Among 45 Sites

Science 37 enrollment: 33
Avg. brick & mortar enrollment: <1 pt/site

Scan to Learn More about Our Direct-to-Patient Site.

www.science37.com

FDA INSPECTED

The First & Only FDA-Inspected Direct-to-Patient Site

Science 37

Case Study: Narcolepsy

Phase 3 | Rare Disease, Neurology

Closed Enrollment

5 Months Early

contributed 77% of the required completers (n=43) for interim analysis

Performance Summary

	Screened	Enrolled
Science 37	91	33
All brick & mortar Sites	69	27
Total	**160**	**60**
Science 37 Contribution	56.0%	55.0%

Site Performance Distribution



Partnership with Catalent

Catalent

Science 37 partnered with Catalent to support its Direct-to-Patient Clinical Trial Site model by delivering reliable and efficient logistics for study medications. Catalent tailored its services to meet both protocol and patient-specific needs, ensuring investigational therapies were shipped successfully and received securely at participants' homes.

This collaboration was especially critical for a study focused on narcolepsy, where patient contact posed a unique challenge. To ensure successful delivery, Catalent's team proactively coordinated with patients to confirm they were awake and available at the time of receipt. Their persistence in outreach—repeatedly contacting patients until confirmation was secured—helped guarantee that medications were delivered securely and on time. By overcoming both geographic and condition-specific logistical barriers, this partnership played a vital role in the study's operational success and patient experience.

Scan to Learn More about Our Direct-to-Patient Site.

www.science37.com

FDA INSPECTED

The First & Only FDA-Inspected Direct-to-Patient Site